BPC 157: Experimental Peptide Creates Risk for Athletes Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement Stevens & Lee The peptide problem: Hype is outrunning the evidence